Objective: Metastatic disease is common in medullary thyroid carcinoma (MTC) and it is usually detected by raising calcitonin and carcinoembryonic antigen (CEA) levels. Nuclear medicine imaging has an important role in lesion identification/characterisation. We aim to compare Ga-DOTANOC PET/CT and F-FDG PET/CT performance and to explore the correlations between tumoral markers and functional imaging.

Methods: This a retrospective cross-sectional study including 13 patients with MTC and high calcitonin/CEA levels that underwent both Ga-DOTANOC PET/CT and F-FDG PET/CT.

Results: Ga-DOTANOC PET/CT identified MTC metastases in 2twopatients that were F-FDG-negative (sensitivity of 69.2% vs. 53.9%, respectively). Ga-DOTANOC PET/CT also detected a higher number of lesions than F-FDG PET/CT in seven patients, with only one patient showing the opposite pattern. Both differences lacked statistical significance (p = 0.50 and p = 0.86, respectively) but Ga-DOTANOC PET/CT better performance allowed changes in patients' management. Ga-positive/F-FDG-negative patients were the ones with the lowest calcitonin doubling time and presented a CEA doubling time >24 months, while the patient with more F-FDG-positive lesions was the one with the highest CEA/calcitonin ratio. The number of lesions found in Ga-DOTANOC PET/CT were correlated with calcitonin levels (r = 0.73; p < 0.01) but not with CEA ones (r = 0.42; p = 0.15). The number of F-FDG hypermetabolic focus were correlated with CEA levels (r = 0.60; p < 0.05) but not with calcitonin (r = 0.48; p = 0.09).

Conclusions: This is the first study to describe a positive correlation between Ga-positive lesions and calcitonin levels and between F-FDG-positivity and CEA levels. Tumoral markers pattern in metastatic MTC could help clinicians to decide which exam to perform first.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-019-01846-8DOI Listing

Publication Analysis

Top Keywords

ga-dotanoc pet/ct
24
f-fdg pet/ct
12
pet/ct
9
medullary thyroid
8
thyroid carcinoma
8
correlations tumoral
8
pet/ct f-fdg
8
number lesions
8
ga-dotanoc
7
ga-dotanoc f-fdg
4

Similar Publications

Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.

View Article and Find Full Text PDF

Comparison of Ga-DOTANOC and F-FDOPA PET/CT for Detection of Recurrent or Metastatic Paragangliomas.

Radiol Imaging Cancer

January 2025

From the Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, 200032 Shanghai, China; and Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.

Purpose To evaluate the diagnostic performance of gallium 68 (Ga)-DOTA-NaI3-octreotide (Ga-DOTANOC) and fluorine 18 (F)-fluoro-l-3,4-dihydroxyphenylalanine (F-FDOPA) PET/CT in detecting recurrent or metastatic paragangliomas. Materials and Methods This single-center retrospective study included patients with paragangliomas who underwent both Ga-DOTANOC PET/CT and F-FDOPA PET/CT between August 2021 and December 2023. The diagnostic performance of these two tracers in detecting recurrent or metastatic tumors was compared using several metrics, including sensitivity, negative predictive value, and accuracy.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effectiveness of the Q.Clear algorithm, specifically the β-level settings, for enhancing image quality in PET/CT scans for patients with neuroendocrine tumors.* -
  • Compared to standard reconstruction, the β1600 setting showed superior performance in overall image quality and in detecting small lesions (less than 1 cm).* -
  • Results indicated that patients with positive PET findings in discordant lesions were confirmed malignant, highlighting the importance of using β1600 reconstruction for accurate diagnosis.*
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the safety and effectiveness of 177 Lu-DOTATATE therapy in children and young adults suffering from metastatic or inoperable neuroendocrine tumors (NETs).
  • A total of 19 young patients treated with a median of 4 cycles showed an objective response rate of 41% and a disease control rate of 94%, with manageable adverse effects primarily categorized as Grade 1 and 2.
  • The results indicate promising 5-year progression-free survival and overall survival rates of 54% and 63%, respectively, suggesting that 177 Lu-DOTATATE is a viable treatment option for this demographic.
View Article and Find Full Text PDF

Background: The value of somatostatin-analogon PET tracers in theranostics in cranial meningioma has been demonstrated in several studies; however, the value of semi-quantitative parameters for therapy and patient outcome is still unclear.

Methods: A retrospective study was performed comparing measured semi-quantitative Ga-DOTANOC PET/CT parameters (maximum standardized uptake value = SUVmax, mean standardized uptake value = SUVmean, and metabolic tumor volume = MTV) and calculated ratios (SUVmax tumor to pituitary gland and SUVmax tumor to superior sinus sagittalis), versus the WHO grades and overall outcome. Patients with histological confirmed meningioma or high probability for meningioma in the previous cranial MRI were eligible.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!